Genentech: Cary Austin | Senior Principal Scientist (Pathology-Collaborative), Pathology

Scientists / Our Scientists

"At Genentech, we strive to address unmet medical needs through innovative scientific discovery and tireless focus on translating discovery to medicines that help patients in need. I feel fortunate to be contributing to this important effort and to be collaborating with some of the best and brightest minds in science and medicine."

Years at Genentech

Publications

Awards & Honors

I completed a combined MD-PhD program at Albert Einstein College of Medicine in 1998 and an Anatomic Pathology Residency and Autopsy Fellowship at Stanford University Hospital in 2001. During my last year at Stanford, I began a postdoctoral fellowship in the laboratory of Richard H. Scheller and in 2001, moved with the laboratory to Genentech, where I investigated endocytosis and intracellular trafficking of cell surface receptors targeted by cancer therapeutics and armed antibodies. I completed the fellowship in 2005 and joined the Department of Pathology at Genentech, where I have since been providing collaborative pathology support for a variety of pipeline research and development programs and academic-focused projects in basic science, mostly in the areas of Immunology and Infectious Diseases.

Featured Publication

Preclinical Safety Profile of a Depleting Antibody against CRTh2 for Asthma: Well Tolerated Despite Unexpected CRTh2 Expression on Vascular Pericytes in the Central Nervous System and Gastric Mucosa.

Toxicol Sci. 2016 Jul;152(1):72-84.

Rajapaksa KS, Huang T, Sharma N, Lui S, Solon M, Reyes A, Paul S, Yee A, Tao J, Chalasani S, Bien-Ly N, Barck K, Carano RD, Wang J, Rangell L, Bremer M, Danilenko DM, Katavolos P, Hotzel K, Reif K, Austin CD.

View Abstract

As a research pathologist, I use a combination of cutting edge molecular labeling and imaging technologies, in addition to more traditional tissue histology, to formulate and address tissue-based scientific questions contributing to the discovery and evaluation of new therapeutic targets, therapies designed specifically to those targets, and tissue biomarkers developed to predict therapeutic efficacy and/or monitor pharmacodynamic activity of the therapy. I’ve work collaboratively on many project teams over the years ranging from early discovery research through to late stage clinical trials. My focus is on allergic, inflammatory, and infectious diseases, with particular interest in asthma and systemic lupus nephritis.

Inhibition of miR-99a-5p prevents allergen-driven airway exacerbations without compromising type-2 memory responses in the intestine following helminth infection

Mucosal Immunology, ISSN: 19353456 19330219

Lewis J. Entwistle; Helena Aegerter; Stephanie Czieso; Eleni Amaniti; Riccardo Guidi; Abdul Sesay; Nikolay Nikolov; Probir Chakravaty; Alison Huynh; Jessica Mills; Sean Flanagan; Shannon Hambro; Victor Nunez; Yi Cao; Christine Clarke; Angela Martzall; Laurie Leong; Dennis Wilson; Cary D. Austin; Mark S. Wilson

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Cary Austin

Senior Principal Scientist (Pathology-Collaborative), Pathology

Featured Publication

Preclinical Safety Profile of a Depleting Antibody against CRTh2 for Asthma: Well Tolerated Despite Unexpected CRTh2 Expression on Vascular Pericytes in the Central Nervous System and Gastric Mucosa.